If you experience fatigue, shortness of breath, or dizziness, hematocrit helps distinguish whether it stems from anemia (too few RBCs) or another cause. If you have a family history of polycythemia or take testosterone therapy, elevated hematocrit becomes a risk signal you should track. If you're an endurance athlete or live at high altitude, hematocrit contextualizes your oxygen-carrying capacity and thrombotic risk. For anyone starting a longevity program, hematocrit is a foundational marker: it reveals whether your blood can deliver oxygen efficiently and whether it has shifted into a viscosity range that increases clot risk.

Hematocrit matters especially if you have symptoms of anemia (iron deficiency, B12 or folate deficiency, chronic disease, bleeding, hemolysis) or signs of secondary polycythemia (sleep apnea, smoking, chronic hypoxia). It also matters if you're male on testosterone replacement therapy, because excess androgens drive erythropoiesis and elevate hematocrit, which compounds thrombotic risk in susceptible people.

Standard vårdcentral tests measure hematocrit automatically as part of a complete blood count (CBC). Longitudinal tracking across years reveals patterns: is your hematocrit stable, trending down (concerning for iron loss or bone marrow dysfunction), or trending up (concerning for polycythemia or dehydration patterns).

• Measures oxygen-carrying capacity directly. Hematocrit quantifies the fractional volume of RBCs in blood. Higher hematocrit improves oxygen delivery to tissues; too-low hematocrit impairs oxygen transport and manifests as fatigue or dyspnea. Normal hematocrit is a prerequisite for sustained energy and exercise performance.

• Distinguishes anemia from dehydration. Fatigue, dizziness, or pallor could stem from true anemia (low RBC production) or pseudo-anemia (high plasma volume from overhydration). Hematocrit paired with hemoglobin, RBC count, and MCV clarifies the mechanism. Low hematocrit + low hemoglobin + low RBC = true anemia. Low hematocrit + normal hemoglobin + normal RBC = hemodilution or pregnancy.

• Flags iron deficiency and nutritional anemias. Progressive decline in hematocrit often signals iron, B12, or folate deficiency before symptoms become severe. Pairing hematocrit with ferritin, serum iron, and B12 reveals whether anemia is iron-driven or caused by other nutritional gaps or chronic disease.

• Identifies secondary polycythemia risk. Elevated hematocrit can signal chronic hypoxia (sleep apnea, COPD, high altitude, smoking), erythropoietin-secreting tumors, or testosterone excess from supplementation. Recognizing polycythemia early is crucial because elevated hematocrit increases blood viscosity and thrombotic risk.

• Monitors testosterone therapy safety. Men on TRT or exogenous androgens experience erythropoiesis stimulation and hematocrit rise. Periodic hematocrit testing is essential to detect polycythemia, prevent thrombotic complications, and adjust testosterone dosing if needed.

• Predicts thrombotic and cardiovascular risk. Hematocrit >0.52 L/L in men or >0.48 L/L in women increases blood viscosity, endothelial shear stress, and platelet activation, raising myocardial infarction and stroke risk. Conversely, very low hematocrit impairs oxygen delivery and increases cardiac workload.

The biology of red blood cells and oxygen transport. Hematocrit is the volume fraction of mature red blood cells (erythrocytes) in whole blood. RBCs contain hemoglobin, an iron-containing protein that binds and carries oxygen from the lungs to every tissue. Higher hematocrit means more RBCs per unit blood volume and thus greater oxygen-carrying capacity. The body maintains hematocrit within a narrow range through erythropoietin (EPO), a hormone released by the kidneys in response to hypoxia. If tissue oxygen falls, the kidneys sense it and increase EPO secretion, stimulating bone marrow to produce more RBCs. If oxygen is abundant or hematocrit rises too high, EPO drops and RBC production slows.

Why hematocrit and hemoglobin differ, and why both matter. Hematocrit is the RBC volume fraction; hemoglobin is the oxygen-carrying protein inside each RBC. A person can have high hemoglobin but low hematocrit if RBCs are unusually large (high MCV, as in macrocytic anemia from B12 deficiency), or normal hemoglobin but low hematocrit if RBC count is simply low (microcytic anemia from iron deficiency with small RBCs). For complete assessment of oxygen transport, all three must be considered: hematocrit (volume), hemoglobin (protein amount), and RBC count and indices (MCV, MCH, MCHC) that reveal RBC size and content. Together, these paint a complete picture of whether anemia is nutritional, hemolytic, or from bone marrow failure.

Direct measurement vs historical calculation. Modern hematology analyzers measure hematocrit directly by electronic cell counting: RBCs are counted individually and their mean volume is multiplied by their count to derive hematocrit. Older labs calculated hematocrit indirectly from hemoglobin (using the formula: Hct = Hb × 3) or packed them down in a centrifuge tube. Direct measurement is more accurate, especially in conditions with abnormal RBC indices or cold agglutinins.

• Identifies anemia that impairs energy and cognition. Even mild anemia (hematocrit 0.35–0.38 L/L) impairs oxygen delivery to brain and muscle, causing fatigue, reduced exercise capacity, and diminished cognitive performance. Because anemia is often correctable through iron, B12, or folate supplementation, identifying it early prevents months or years of reduced quality of life and performance.

• Flags elevated hematocrit as a thrombotic warning sign. Hematocrit >0.50 L/L in men correlates with increased blood viscosity, platelet hyperactivity, and reduced endothelial nitric oxide availability — all pro-thrombotic. People with hematocrit in the 0.50–0.55 range have measurably elevated myocardial infarction and stroke risk. This is especially important for men on testosterone therapy, where androgens directly stimulate erythropoiesis and drive hematocrit upward; monitoring prevents thrombotic events.

• Reveals secondary polycythemia from occult hypoxia. Sleep apnea, undiagnosed COPD, or high-altitude living can elevate hematocrit through chronic hypoxia-driven EPO release. Finding this pattern via hematocrit-guided screening can lead to sleep study referral or respiratory evaluation, preventing sudden cardiovascular events.

• Tracks nutritional and bone marrow status over time. Longitudinal hematocrit trending is more informative than a single snapshot. Declining hematocrit over years despite stable lifestyle signals iron loss (occult GI bleeding, heavy menses), nutritional insufficiency (B12, folate, copper), or bone marrow dysfunction. Rising hematocrit in someone not on TRT may signal occult EPO-secreting pathology or chronic hypoxia worth investigating.

• Standard Swedish clinical reference (men 0.40–0.50 L/L, women 0.35–0.46 L/L): These are the ranges reported by Standard Swedish clinical labs and represent what a vårdcentral would call “normal.” Values within these ranges are typically not flagged. However, this range includes both optimal and borderline high values.

• Loovi optimal (longevity baseline, men 0.40–0.48 L/L, women 0.35–0.44 L/L): This is the range associated with the lowest cardiovascular event risk in large cohort studies. It balances oxygen-carrying capacity (avoiding anemia) with blood viscosity and thrombotic risk (avoiding polycythemia). For men, remaining below 0.48 L/L substantially reduces thrombotic risk. For women, 0.35–0.44 L/L is the sweet spot for both energy and clot prevention.

• Elevated / monitored (men >0.48 L/L, women >0.44 L/L): Values above these thresholds warrant investigation for secondary causes: sleep apnea, smoking, chronic hypoxia, or (in men) testosterone supplementation. For men on TRT, hematocrit >0.54 L/L is associated with substantially elevated thrombotic risk and typically triggers testosterone dose reduction or phlebotomy.

The step from optimal to elevated represents a meaningful shift in blood viscosity and thrombotic risk. In men, moving from 0.48 to 0.52 L/L increases relative myocardial infarction risk by approximately 20–30% over 5 years. For longevity, aiming for the Loovi optimal range is aligned with the lowest all-cause mortality across primary prevention studies.

Low (<0.35 L/L for women, <0.40 L/L for men). This indicates anemia — fewer or smaller RBCs than normal. Symptoms may include fatigue, dyspnea on exertion, dizziness, or pallor. The cause could be iron deficiency (most common), B12 or folate deficiency, chronic disease (kidney dysfunction, autoimmune disease), bone marrow suppression, hemolysis, or acute bleeding. Paired markers clarify: low hemoglobin + low RBC + low MCV = iron deficiency; low hemoglobin + low RBC + high MCV = B12 or folate deficiency; low hemoglobin + normal RBC + normal MCV = hemolysis or bone marrow disease. Ferritin, serum iron, B12, and reticulocyte count guide the workup.

Optimal (men 0.40–0.48 L/L, women 0.35–0.44 L/L). This range represents the healthiest hematocrit for longevity and energy. Oxygen-carrying capacity is adequate, blood viscosity is not elevated, and thrombotic risk is minimized. People in this range typically report normal energy and exercise capacity. If energy is still low despite hematocrit in this range, consider iron stores (ferritin), B12 status, thyroid function, or metabolic fitness.

Elevated (men 0.48–0.54 L/L, women 0.44–0.50 L/L). This is above optimal and warrants investigation. Causes include dehydration (pseudo-polycythemia from plasma volume loss), chronic hypoxia (sleep apnea, smoking, altitude), testosterone supplementation, or early secondary polycythemia. If you're well-hydrated and not on TRT, elevated hematocrit suggests sleep apnea or respiratory pathology and warrants sleep study or pulmonary evaluation. Phlebotomy or hydration adjustment may be indicated, depending on the cause.

Very High (>0.54 L/L for men, >0.50 L/L for women). This represents polycythemia vera or very severe secondary polycythemia. Blood viscosity is substantially elevated; thrombotic risk (MI, stroke, DVT) is markedly increased. In men on testosterone therapy, values this high warrant immediate testosterone dose reduction. In others, polycythemia vera or paraneoplastic EPO secretion must be ruled out via bone marrow examination, JAK2 mutation testing, or EPO and iron studies.

Factors that influence hematocrit. Acute dehydration raises hematocrit artifactually (true hematocrit is unchanged, but plasma volume has fallen). Prolonged sitting, intense exercise within 24 hours, or high altitude can transiently raise hematocrit. Pregnancy lowers hematocrit due to plasma expansion (hemodilution). Menstrual blood loss can lower hematocrit in women with heavy periods. Altitude exposure or chronic hypoxia elevates hematocrit through EPO stimulation. Testosterone supplementation raises hematocrit in days to weeks. Recent phlebotomy or transfusion obviously affects values. For the most accurate baseline, test when well-hydrated, at least 48 hours post-exercise, and (for women) not during or immediately after menstruation.

• Iron deficiency and nutritional anemia. Iron is essential for hemoglobin synthesis. Low dietary iron, poor iron absorption (celiac disease, pernicious anemia, achlorhydria), or blood loss (heavy menses, occult GI bleeding, repeated blood donation) depletes iron stores and suppresses RBC production. This is the most common cause of low hematocrit worldwide. Ferritin <30 µg/L or serum iron <10 µmol/L with low hematocrit confirms iron-deficiency anemia. Supplementation or transfusion corrects it.

• B12 and folate deficiency. Vitamin B12 and folate are required for DNA synthesis and RBC maturation. Deficiency produces macrocytic anemia (large RBCs, high MCV) with low hematocrit. Causes include pernicious anemia (intrinsic factor antibodies), bacterial overgrowth causing B12 malabsorption, strict veganism, or folate insufficiency from poor diet or methotrexate therapy. These are readily corrected by supplementation or dietary changes, but diagnosis requires serum B12 and folate levels.

• Chronic kidney disease and low erythropoietin. The kidneys produce EPO in response to hypoxia. In chronic kidney disease, EPO production declines, bone marrow receives fewer signals to make RBCs, and hematocrit drops. This is a progressive, irreversible anemia unless EPO-stimulating agents (ESA) or iron supplementation are provided. Patients with renal disease require regular hematocrit monitoring.

• Secondary polycythemia from chronic hypoxia. Sleep apnea, COPD, high-altitude living, or heavy smoking cause chronic tissue hypoxia, triggering EPO release and RBC overproduction. Hematocrit rises, sometimes substantially. The path to treatment is to address the hypoxia: sleep apnea management, smoking cessation, COPD therapy. In some cases, phlebotomy is needed to reduce viscosity risk while underlying causes are being treated.

• Testosterone supplementation and androgens. Testosterone directly stimulates erythropoiesis in bone marrow. Men on TRT typically see hematocrit rise by 0.03–0.08 L/L within weeks. Very high doses or long-acting preparations raise hematocrit further. This is why men on TRT need periodic hematocrit monitoring; values >0.54 L/L warrant dose reduction or phlebotomy to prevent thrombosis.

Ensuring adequate iron intake and absorption. Hematocrit depends on adequate iron supply. Red meat, poultry, and fish provide highly absorbable heme iron; legumes, leafy greens, and fortified grains provide non-heme iron (absorbed less efficiently, especially without vitamin C). Cooking in cast iron increases iron content. Absorption is impaired by phytates (legumes, grains), tannins (tea, coffee), calcium, and proton-pump inhibitors. For someone with low hematocrit and low ferritin, iron supplementation (ferrous sulfate or comparable salt) or dietary optimization restores hematocrit within 4–8 weeks if iron deficiency is the sole cause. Vitamin C enhances iron absorption; pairing supplemental iron with orange juice or ascorbic acid improves bioavailability.

B12 and folate sufficiency. B12 is found in animal products and fortified foods; vegans require supplementation (oral cyanocobalamin, sublingual methylcobalamin, or IM injections). Folate is abundant in leafy greens, legumes, and whole grains. A standard Western diet is usually adequate in folate, but vegans, people with celiac disease, and those on methotrexate may be at risk. Serum B12 <200 pmol/L or folate <5.4 nmol/L warrants supplementation or dietary change; correction restores hematocrit within 6–12 weeks in macrocytic anemia.

Managing secondary causes of polycythemia. If hematocrit is elevated, the first step is to identify the mechanism. Sleep apnea screening (sleep study if symptomatic), smoking cessation, and high-altitude deacclimatization address hypoxia-driven polycythemia. Testosterone dosing should be individualized: men on TRT with hematocrit >0.52 L/L often benefit from dose reduction, switching to lower-dose transdermal patches, or extending dosing intervals. Some require phlebotomy (therapeutic bloodletting) if hematocrit creeps above 0.54 L/L. For polycythemia vera (a myeloproliferative disorder), phlebotomy and aspirin are standard to reduce viscosity and thrombotic risk.

Hydration status and plasma volume. Chronic dehydration raises hematocrit artificially (pseudo-polycythemia). Ensure adequate daily fluid intake — roughly 30–35 mL per kg body weight, or more if exercising or in hot climates. Electrolyte balance (sodium, potassium, magnesium) matters; inadequate electrolytes can impair fluid retention. Proper hydration is especially important for people on TRT or at high altitude, where hematocrit is naturally elevated; adequate fluid intake prevents viscosity from becoming problematic.

Training and cardiovascular fitness. Endurance training at sea level can increase VO2 max and modestly raise hematocrit through natural erythropoiesis stimulation. This is physiologic and beneficial for oxygen delivery. At high altitude, acclimatization increases hematocrit further through EPO stimulation — a normal adaptive response that improves oxygen transport but also increases viscosity, requiring monitoring and hydration.

The right approach depends on whether hematocrit is low (requiring iron, B12, folate, or EPO support) or elevated (requiring hypoxia assessment, testosterone dosing review, or phlebotomy). These are precisely the adjustments a Loovi longevity doctor tailors during consultation, pairing hematocrit with hemoglobin, RBC indices, iron studies, and the full clinical picture.

Hematocrit tells you how much of your blood is made up of RBCs, but it doesn't tell you whether your RBCs are healthy, why they're low or high, or how well they transport oxygen. A hematocrit of 0.42 L/L could indicate robust health or could mask underlying iron deficiency if RBCs are small (low MCV). Similarly, a hematocrit of 0.50 L/L could be benign polycythemia from altitude living or a dangerous signal of polycythemia vera or paraneoplastic disease. Without hemoglobin, RBC count, and RBC indices (MCV, MCH, MCHC), you cannot diagnose the cause of abnormal hematocrit. Without ferritin and serum iron, you cannot assess iron stores. Without B12 and folate, you cannot rule out macrocytic anemia. Without EPO, JAK2, and bone marrow studies, you cannot distinguish secondary from primary polycythemia.

The Loovi Membership measures 120+ biomarkers annually, including the complete CBC (hematocrit, hemoglobin, RBC count, WBC, platelets, and all RBC indices), iron metabolism (ferritin, serum iron, TIBC, transferrin saturation), B12 and folate, and reticulocyte count for bone marrow assessment. Paired with unrushed 1-on-1 longevity doctor consultations, physical performance tests (aerobic capacity, strength), and an evolving personalized health plan, Loovi hands off the clinical interpretation and personalization to experts. From 295 SEK/month, Friskvårdsbidrag-approved, with drop-in testing at 80+ Swedish clinics and results in 3 days.